MAO-B inhibitors in Parkinson's disease
Olanow, C.W.
Advances in Neurology 60: 666-671
1993
ISSN/ISBN: 0091-3952 PMID: 8420207 Document Number: 420496
Document emailed within 1 workday
Related Documents
Youdim, M.B. 1986: Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease Journal of Neural Transmission. Supplementum 22: 91-105Ruggieri, S.; Fabbrini, G.; Bramante, L.; DePandis, F.; Stocchi, F.; Barbanti, P.; Vacca, L.; Manfredi, M. 1996: An open study with reversible MAO-A inhibitors in complicated Parkinson's disease Advances in Neurology 69: 595-598
Rabasseda, X. 1999: Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies Drugs of Today 35(9): 701-717
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Sale, P.; De Pandis, M.F.; Vimercati, S.L.; Sova, I.; Foti, C.; Tenore, N.; Fini, M.; Stocchi, F.; Albertini, G.; Franceschini, M.; Galli, M. 2013: The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects European Journal of Physical and Rehabilitation Medicine 49(2): 161-167
Larsson, A. 2006: Good evidence for benefits of cholinesterase inhibitors in Parkinson dementia is still missing Lakartidningen 103(19): 1537; Discussion: 1537-1538
Mastaglia, F.L.; Masters, C.L.; Beyreuther, K.; Kakulas, B.A. 1989: Deposition of Alzheimer's disease amyloid (A4) protein in the cerebral cortex in Parkinson's disease Progress in Clinical and Biological Research 317: 475-484
Braak, H.; Braak, E.; Yilmazer, D.; de Vos, R.A.; Jansen, E.N.; Bohl, J. 1996: New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease Journal of Neural Transmission. Supplementum 48: 1-6
Schoenberg, B.S. 1987: Descriptive epidemiology of Parkinson's disease: disease distribution and hypothesis formulation Advances in Neurology 45: 277-283
Groves, M.S.; Forrest, D.V. 2005: Parkinson's disease as a model for psychosocial issues in chronic neurodegenerative disease Advances in Neurology 96: 65-83
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Nishinaka, T.; Kuroda, S.; Hayashi, Y.; Fujisawa, Y. 1990: Motor neuron disease with Parkinson's disease--case report Rinsho Shinkeigaku 30(11): 1252-1255
Kuno, S. 2004: Parkinson's disease: the disease concept, etiology and diagnostic bases Nihon Rinsho. Japanese Journal of Clinical Medicine 62(9): 1603-1607
Elizan, T.S.; Yahr, M.D. 1988: Parkinson's disease, Alzheimer's disease, and the aging brain. Introduction Mount Sinai Journal of Medicine new York 55(1): 1-2
Alpert, M.; Rosen, A.; Welkowitz, J.; Sobin, C.; Borod, J.C. 1989: Vocal acoustic correlates of flat affect in schizophrenia. Similarity to Parkinson's disease and right hemisphere disease and contrast with depression British Journal of Psychiatry. Suppl 4: 51-56
Rasmussen, V.G.; Dupont, E.; Østergaard, K.; Egeblad, H. 2006: Valvular heart disease associated with the treatment of Parkinson disease Ugeskrift for Laeger 168(26-32): 2542-2544
Hoffman, R.M. 1997: Methioninase: a therapeutic for diseases related to altered methionine metabolism and transmethylation: cancer, heart disease, obesity, aging, and Parkinson's disease Human Cell 10(1): 69-80
Keppel Hesselink, J.M. 1991: A variable disease? Parkinson's disease since 1817 Nederlands Tijdschrift Voor Geneeskunde 135(22): 998-1003